Grace Gene Therapy

Company Overview

Snapshot

Founded in November 2024 by Fadi Assaf, Grace Gene Therapy operates with 1–10 employees. The company has secured one funding round from one investor, NGT HealthCare II, in November 2024, focusing on its gene therapy treatment for Parkinson's Disease.

Business overview

Grace Gene Therapy is developing a gene therapy treatment for Parkinson’s disease, utilizing a first-in-class chemogenetic agent. This biotech treatment aims to correct neural network dysfunctions caused by Parkinson’s by precisely modulating specific brain regions, such as the basal ganglia, through Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). The company operates within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology and Drugs Discovery & Development, with a focus on pharmaceutical applications in life sciences.

Company Intelligence Q&A

When was Grace Gene Therapy founded?

Grace Gene Therapy was founded in November 2024.

Who is the founder of Grace Gene Therapy?

Fadi Assaf is the Co-founder & CEO of Grace Gene Therapy.

What is Grace Gene Therapy's primary focus?

Grace Gene Therapy is focused on developing a gene therapy treatment solution for Parkinson's Disease.

Which investor participated in Grace Gene Therapy's funding round?

In November 2024, Grace Gene Therapy received funding from NGT HealthCare II in a Pre-Seed round.

What technology does Grace Gene Therapy utilize for its treatment?

Grace Gene Therapy utilizes chemogenetic agents and DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) to selectively target diseased brain regions and fix neural network problems associated with Parkinson's disease.